Image generated by AI
AI Insight
GSK's drug "bepi" has demonstrated better than anticipated results in efficacy trials for achieving functional cure of hepatitis B virus infections. The treatment shows promise in suppressing HBV to undetectable levels where patients no longer require ongoing therapy, though the article notes its global impact may be constrained.
Why it matters
A functional cure for hepatitis B would be a significant advancement over current treatments that only suppress the virus and require lifelong administration. However, the limited global impact suggests potential barriers related to cost, access, or applicability to all HBV patient populations.
GSK’s “bepi” performs better than expected in efficacy trials, but its global impact is likely limited
Source: New drug ‘functionally cures’ many hepatitis B virus infections